New combo could spare rectal cancer patients from radiation side effects
NCT ID NCT06688786
First seen Jan 28, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tests a new approach for people with a common type of locally advanced rectal cancer (MSS/pMMR). Instead of standard radiation, participants receive a combination of chemotherapy (mFOLFOX6) and an immunotherapy drug (PD-1 antibody) before surgery. The goal is to shrink the tumor and reduce the risk of cancer returning, while avoiding radiation-related side effects like bowel problems and poor anal function. The trial enrolls 30 adults aged 18-75 with stage cT3-4 or node-positive rectal cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200092, China
Conditions
Explore the condition pages connected to this study.